Literature DB >> 12573191

Benefits of simvastin in cholesterol lowering.

John A Farmer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12573191     DOI： 10.1007/s11883-003-0078-y

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


× No keyword cloud information.
  9 in total

1.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

Authors:  G G Schwartz; A G Olsson; M D Ezekowitz; P Ganz; M F Oliver; D Waters; A Zeiher; B R Chaitman; S Leslie; T Stern
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

2.  Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

Authors:  B Pitt; D Waters; W V Brown; A J van Boven; L Schwartz; L M Title; D Eisenberg; L Shurzinske; L S McCormick
Journal:  N Engl J Med       Date:  1999-07-08       Impact factor: 91.245

3.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

4.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

5.  Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.

Authors:  Vasilios G Athyros; Athanasios A Papageorgiou; Bodosakis R Mercouris; Valasia V Athyrou; Athanasios N Symeonidis; Elias O Basayannis; Dimokritos S Demitriadis; Athanasios G Kontopoulos
Journal:  Curr Med Res Opin       Date:  2002       Impact factor: 2.580

6.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

7.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

8.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

9.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321
  9 in total
  1 in total

Review 1.  Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases.

Authors:  Goran Bjelakovic; Dimitrinka Nikolova; Lise Lotte Gluud; Rosa G Simonetti; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.